Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Adcentrx, a San Diego-Shanghai Company, Raises $38 Million for ADC Portfolio

publication date: Apr 26, 2023

Adcentrx Therapeutics closed a $38 million Series A+ round from a group of China VC investors to advance its portfolio of ADC therapeutics for cancer and other life-threatening diseases. The company, located in San Diego and Shanghai, uses its experience in ADC drug development along with chemistry and biology expertise to develop ADC candidates that solve problems associated with earlier ADC products. ADRX-0706, Adcentrx’s lead candidate, is expected to start Phase I trials later this year. Eight Roads led the funding, with participation from F-Prime Capital, ABio-X, Delta Capital and Trinity Innovation Fund. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital